Search CommunityWalk:


Glycotex, Inc.

2275 Research Blvd., Suite 500
Rockville, MD 20850, USA

Category: Dermatology; Burns & Wound Care

Used in the following map:

Maryland Biotech Industry Map

Glycotex, Inc. is a biopharmaceutical company focused on the discovery and development of drugs intended to accelerate human wound healing and tissue repair in acute and chronic wounds. It is a part of Novogen Limited.

Glycotex's proprietary technology is based on the extraction of yeast cells containing the carbohydrate (1-3)(1-6)-Beta-glucan in a specific configuration and size. The company has developed significant expertise with respect to engineering, characterizing and producing the optimal forms of this molecule for use in wound healing. A key component of its proprietary technology is an understanding of the structure-function relationship of the (1-3)(1-6)-beta-glucan molecule and its interaction with target cells in the wound.

Glycotex's lead product GLYC-101 is indicated for the treatment of burn wounds, post surgical wounds, diabetic ulcers and chronic venous ulcers. The active pharmaceutical ingredient in GLYC-101 is a glucoprime. Glucoprime has a unique mechanism of action that stimulates the action of macrophages by binding to the Dectin-1 receptor expressed on the critical cells involved in the wound healing process.

Glycotex has an agreement with Advanced Medical Solutions Group plc (AMS).